Taking quinazoline as a general support-nog to design potent and selective kinase inhibitors: Application to FMS-like tyrosine kinase 3

ChemMedChem

Volumn 5, Issue 4, 2010, Pages 513-516

  Li, Wei Wei ^a,b   Chen, Jin Juan ^a   Zheng, Ren Lin ^a   Zhang, Wen Qin ^a   Cao, Zhi Xing ^a   Yang, Ling Ling ^a,b   Qing, Xiao Yu ^a   Zhou, Liang Xue ^a   Yaeng, Li ^a   Yu, Luo Ding ^a   Chen, Li Juan ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

De novo design; FMS like tyrosine kinase 3; Inhibitors; Kinases; Selectivity

Indexed keywords

2 (6,7 DIMETHOXYQUINAZOLIN 4 YLTHIO)THIAZOLE; 6,7 DIMETHOXY 4 (THIOPHEN 2 YLTHIO)QUINAZOLINE; 6,7 DIMETHOXY 4 [2 (THIOPHEN 2 YL)ETHOXY]QUINAZOLINE; AC 220; CD135 ANTIGEN; DOVITINIB; ERLOTINIB; FMS LIKE TYROSINE KINASE 3 INHIBITOR; GEFITINIB; IMATINIB; KW 2449; LAPATINIB; LESTAURTINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; SEMAXANIB; SORAFENIB; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG DESIGN; DRUG INDUSTRY; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; FMS-LIKE TYROSINE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 77950677291     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900537     Document Type: Article

References (24)

1. For recent reviews, see: A) M. E. M. Noble, J. A. Endicott, L. N. Johnson, Science 2004, 303, 1800-1805
2. b) C. Zhang, S.-H. Kim, Comput. Struct. Appr. Drug Discovery 2008, 349, 349-365
3. C) I. Akritopoulou-Zanze, P. J. Hajduk, Drug Discovery Today 2009, 14, 291-297.
4. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912-1934.
5. J. J.-L. Liao, J. Med. Chem. 2007, 50, 409-424.
6. Y. Liu, N. S. Gray, Nat. Chem. Biol. 2006, 2, 358-364.
7. a) A. C. Backes, B. Zech, B. Felber, B. Klebl, G. Muller, Expert Opin. Drug Discovery 2008, 3, 1409-1425
8. b) A. C. Backes, B. Zech, B. Felber, B. Klebl, G. Muller, Expert Opin. Drug Discovery 2008, 3, 1427-1449.
9. a) C.-H. Yun, T.J. Boggon, Y. Li, S. Woo, H. Greulich, M. Meyerson, M.J. Eck, Cancer Cell 2007, 11, 217-227
10. b) J. Stamos, M. X. Sliwkowski, C. Ei-genbrot, J. Biol. Chem. 2002, 277, 46265-46272
11. C) C. Qiu, M. K. Tarrant, S. H. Choi, A. Sathyamurthy, R. Bose, S. Banjade, A. Pal, W. G. Bornmann, M. A. Lemmon, P. A. Cole, D. J. Leahy, Structure 2008, 16, 460-467.
12. a) A. Pandey, D. L. Volkots, J. W. Rose, J.-C. Yu, A. Hutchaleelaha, K. Abe, A. G. Niel, R. M. Scarborough, J. Med. Chem. 2002, 45, 3772-3793
13. b) A. J. Bridges, H. Zhou, D. R. Cody, G.W. Rewcastle, A. McMichael, H. D. H. Showalter, D. W. Fry, W. A. Denny, J. Med. Chem. 1996, 39, 267-276.
14. O. Rosnet, C. Schiff, M.J. Pebusque, S. Marchetto, C. Tonnelle, Y Toiron, F. Birg, D. Birnbaum, Blood 1993, 82, 1110-1119.
15. S. D. Lyman, L. James, J. Zappone, P. R. Sleath, M. P. Beckmann, T. Bird, Oncogene 1993, 8, 815-822.
16. D. L. Stirewalt, J. P. Radich, Nat. Rev. Cancer 2003, 3, 650-666.
17. S. Mahboobi, A. Uecker, A. Sellmer, C. Cenac, H. Hçcher, H. Pongratz, E. Eichhorn, H. Hufsky, A. Trumpler, M. Sicker, F. Heidel, T. Fischer, C. Stocking, S. Elz, F. D. Bçhmer, S. Dove, J. Med. Chem. 2006, 49, 3101-3115.
18. P. Furet, G. Bold, T. Meyer, J. Roesel, V. Guagnano, J. Med. Chem. 2006, 49, 4451-4454.
19. K. W. Pratz, J. Cortes, G. J. Roboz, N. Rao, O. Arowojolu, A. Stine, Y. Shiot-su, A. Shudo, S. Akinaga, D. Small, J. E. Karp, M. Levis, Blood 2009, 11 3, 3938-3946.
20. D. J. DeAngelo, R. M. Stone, M. L. Heaney, S. D. Nimer, R. L. Paquette, R. B. Klisovic, M. A. Caligiuri, M. R. Cooper, J.-M. Lecerf, M. D. Karol, S. Sheng, N. Holford, P. T. Curtin, B. J. Druker, M. C. Heinrich, Blood 2006, 108, 3674-3681.
21. S. Knapper, A. K. Burnett, T. Littlewood, W. J. Kell, S. Agrawal, R. Chopra, R. Clark, M. J. Levis, D. Small, Blood 2006, 108, 3262-3270.
22. Cerius software package, Accelrys Inc., San Diego, CA (USA):http://accelrys.com.
23. Gold v. 3.2, CCDC, Cambridge (UK): http://www.ccdc.cam.ac.uk.
24. M. Verdonk, J. Cole, M. Hartshorn, C. Murray, R. Taylor, Proteins 2003, 52, 609-623.